MX370372B - Xantinas sustituidas y metodos de uso de las mismas. - Google Patents

Xantinas sustituidas y metodos de uso de las mismas.

Info

Publication number
MX370372B
MX370372B MX2015011617A MX2015011617A MX370372B MX 370372 B MX370372 B MX 370372B MX 2015011617 A MX2015011617 A MX 2015011617A MX 2015011617 A MX2015011617 A MX 2015011617A MX 370372 B MX370372 B MX 370372B
Authority
MX
Mexico
Prior art keywords
methods
substituted xanthines
xanthines
substituted
trpc5
Prior art date
Application number
MX2015011617A
Other languages
English (en)
Other versions
MX2015011617A (es
Inventor
Chenard Bertrand
Gallaschun Randall
Original Assignee
Hydra Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50680155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX370372(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hydra Biosciences Inc filed Critical Hydra Biosciences Inc
Publication of MX2015011617A publication Critical patent/MX2015011617A/es
Publication of MX370372B publication Critical patent/MX370372B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen compuestos, composiciones y métodos para inhibir el canal iónico de TRPC5 y trastornos relacionados con TRPC5.
MX2015011617A 2013-03-15 2014-03-14 Xantinas sustituidas y metodos de uso de las mismas. MX370372B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789724P 2013-03-15 2013-03-15
PCT/US2014/027920 WO2014143799A2 (en) 2013-03-15 2014-03-14 Substituted xanthines and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2015011617A MX2015011617A (es) 2016-04-25
MX370372B true MX370372B (es) 2019-12-11

Family

ID=50680155

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011617A MX370372B (es) 2013-03-15 2014-03-14 Xantinas sustituidas y metodos de uso de las mismas.

Country Status (31)

Country Link
US (7) US9359359B2 (es)
EP (1) EP2970303B3 (es)
JP (1) JP6360149B2 (es)
KR (1) KR102227629B1 (es)
CN (2) CN107082782B (es)
AU (1) AU2014228206C1 (es)
CA (1) CA2899646C (es)
CL (1) CL2015002738A1 (es)
CY (1) CY1119042T1 (es)
DK (1) DK2970303T6 (es)
EA (1) EA028815B1 (es)
ES (1) ES2636835T7 (es)
HR (1) HRP20170840T4 (es)
HU (1) HUE033528T4 (es)
IL (1) IL240216B (es)
LT (1) LT2970303T (es)
MX (1) MX370372B (es)
MY (1) MY189912A (es)
NZ (1) NZ711718A (es)
PE (1) PE20151779A1 (es)
PH (1) PH12015502141B1 (es)
PL (1) PL2970303T6 (es)
PT (1) PT2970303T (es)
RS (1) RS56066B2 (es)
SG (1) SG11201506479TA (es)
SI (1) SI2970303T1 (es)
TW (1) TWI609867B (es)
UA (1) UA117470C2 (es)
UY (1) UY35488A (es)
WO (1) WO2014143799A2 (es)
ZA (1) ZA201505414B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
EP2970303B3 (en) 2013-03-15 2018-08-01 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof
EP3180342B1 (en) * 2014-08-11 2019-06-26 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
GB2553684B (en) 2015-03-27 2020-06-03 Latvian Inst Organic Synthesis Ethynylxanthines, preparation and use for cancer treatment
GB2553685B (en) 2015-03-27 2020-06-10 Latvian Inst Organic Synthesis Novel ethynylxanthines for use as inhibitors of matrix metalloproteinases and angiogenesis
GB2553686B (en) 2015-03-27 2020-06-03 Latvian Inst Organic Synthesis Ethynylxanthines, preparation and use as calcium ion channel modulators
MX380672B (es) * 2015-04-08 2025-03-12 Lewis And Clark Pharmaceuticals Inc Carbamatos de alquinilo sustituidos por xantina/carbamatos inversos como antagonistas de a2b
CN107118586A (zh) * 2016-02-24 2017-09-01 中国科学技术大学 含氮杂环基取代的烯类化合物的用途
GB201702160D0 (en) * 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
WO2018157800A1 (en) * 2017-02-28 2018-09-07 National Institute Of Biological Sciences, Beijing Mlkl inhibitors
US11666577B2 (en) * 2017-02-28 2023-06-06 National Institute Of Biological Sciences, Beijing MLKL inhibitors
CN110997675B (zh) * 2017-07-11 2022-06-07 勃林格殷格翰国际公司 新的取代的黄嘌呤衍生物
CA3093084A1 (en) * 2018-03-05 2019-09-12 Goldfinch Bio, Inc. Imidazodiazepinediones and methods of use thereof
JP7408662B2 (ja) * 2018-12-12 2024-01-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換キサンタン誘導体
JP7502299B2 (ja) * 2018-12-12 2024-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換キサンチン誘導体
CN112979651B (zh) * 2021-04-09 2022-02-01 南京纽邦生物科技有限公司 一种副黄嘌呤的制备方法
CN113354646B (zh) * 2021-07-06 2022-11-15 南开大学 8-芳氧基烷氧基取代黄嘌呤衍生物及其制备方法和应用
CN115636831B (zh) * 2022-10-27 2024-11-08 中国药科大学 稠合嘧啶二酮类化合物、其用途以及药物组合物
CN120379994A (zh) 2022-12-20 2025-07-25 勃林格殷格翰国际有限公司 用于制备7-(4-氯苄基)-1-(3-羟基丙基)-3-甲基-8-(3-(三氟甲氧基)-苯氧基)-3,7-二氢-1h-嘌呤-2,6-二酮的方法
CN118373832B (zh) * 2023-01-20 2025-01-28 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用
WO2024165540A1 (en) 2023-02-06 2024-08-15 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione
KR20250141831A (ko) 2023-02-08 2025-09-29 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 잔틴계 화합물 및 이의 용도
WO2025250920A1 (en) 2024-05-31 2025-12-04 Gfb (Abc), Llc Pyridazinone phosphate compounds, pharmaceutical compositions, and medical uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4304650A1 (de) * 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
JP4191269B2 (ja) 1996-05-17 2008-12-03 興和株式会社 新規なアニリド化合物及びこれを含有する医薬
JPH10318487A (ja) 1997-05-16 1998-12-04 Mitsubishi Gas Chem Co Inc 真空断熱材用ゲッタ
US6075029A (en) * 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
US6187780B1 (en) * 1998-04-16 2001-02-13 Boehringer Ingelheim Pharma Kg Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
JP2002541258A (ja) * 1999-04-09 2002-12-03 セル セラピューティクス インコーポレーテッド インターリューキン−１２シグナルを阻害するための治療用化合物及びその使用方法
CZ200319A3 (cs) * 2000-07-04 2003-05-14 Novo Nordisk A/S Heterocyklické sloučeniny, které jsou inhibitory enzymu DPP-IV
CA2430951A1 (en) 2000-12-07 2002-06-13 Cv Therapeutics, Inc. Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
MXPA03007349A (es) * 2001-02-24 2003-12-04 Boehringer Ingelheim Pharma Derivados de xantina, su preparacion y su empleo como medicamentos.
PT1444233E (pt) * 2001-11-09 2011-09-29 Gilead Palo Alto Inc Antagonistas de receptor de adenosina a2b
WO2004106337A1 (en) * 2003-05-06 2004-12-09 Cv Therapeutics, Inc. Xanthine derivatives as a2b adenosine receptor antagonists
JP2007511528A (ja) 2003-11-13 2007-05-10 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 心肥大および心不全の処置としてのｔｒｐチャネル阻害方法
EP1841448A2 (en) 2004-12-30 2007-10-10 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring beta-cell mass and function
US8143254B2 (en) 2005-02-18 2012-03-27 Cornell Research Foundation, Inc. Methods for modulating ion channels
HRP20100725T1 (hr) * 2005-08-10 2011-01-31 Glaxosmithkline Llc Derivati ksantina kao selektivni agonisti hm74a
ATE459620T1 (de) * 2005-09-06 2010-03-15 Glaxosmithkline Llc Benzimidazolthiophenverbindungen als plk- modulatoren
US20090018148A1 (en) * 2005-12-07 2009-01-15 Ucb Pharma, S.A. Xanthine Derivatives, Processes For Preparing Them And Their Uses
JP5858557B2 (ja) * 2005-12-22 2016-02-10 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 疼痛を処置するためのｔｒｐａ１阻害剤
WO2007084728A2 (en) 2006-01-19 2007-07-26 Abbott Laboratories 2-imino-benzimidazoles
WO2007101213A2 (en) 2006-02-28 2007-09-07 Kalypsys, Inc. Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors
WO2008011518A2 (en) * 2006-07-19 2008-01-24 Diakine Therapeutics, Inc. Encapsulation system
WO2009157938A1 (en) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
EP2467398B1 (en) 2009-08-20 2019-10-09 Poseida Therapeutics, Inc. Trpc4 inhibitors and uses thereof
WO2011114184A1 (en) * 2010-03-15 2011-09-22 Glenmark Pharmaceuticals S.A. Amides of heterocyclic compounds as trpa1 inhibitors
WO2012050641A2 (en) 2010-06-08 2012-04-19 Hydra Biosciences, Inc Use of trpa1 antagonists to prevent or treat infections caused by biological-warfare agents
JP2013023102A (ja) * 2011-07-22 2013-02-04 Panasonic Corp 列車情報提供システム
BR112014002960A2 (pt) * 2011-08-09 2017-02-21 Cubist Pharm Inc inibição de canal de íons potencial receptor transiente trpa1
CN103121970B (zh) 2012-12-04 2015-04-29 中国科学院昆明植物研究所 苯并咪唑及其衍生物，其药物组合物及其在制备抗抑郁药物中的应用
EP2970303B3 (en) 2013-03-15 2018-08-01 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof

Also Published As

Publication number Publication date
BR112015021164A2 (pt) 2017-07-18
AU2014228206B2 (en) 2018-05-10
CL2015002738A1 (es) 2016-06-10
HK1217329A1 (zh) 2017-01-06
EP2970303A2 (en) 2016-01-20
NZ711718A (en) 2020-05-29
PH12015502141A1 (en) 2016-01-25
US9359359B2 (en) 2016-06-07
EA201591615A1 (ru) 2016-05-31
LT2970303T (lt) 2017-07-25
HRP20170840T4 (hr) 2018-11-16
DK2970303T6 (en) 2018-10-08
US20180244674A1 (en) 2018-08-30
SG11201506479TA (en) 2015-09-29
US20160237089A1 (en) 2016-08-18
PE20151779A1 (es) 2015-11-20
US11208409B2 (en) 2021-12-28
WO2014143799A3 (en) 2014-11-06
US20230040259A1 (en) 2023-02-09
WO2014143799A4 (en) 2015-02-12
AU2014228206A1 (en) 2015-09-24
RS56066B2 (sr) 2018-09-28
ES2636835T3 (es) 2017-10-09
EA028815B1 (ru) 2018-01-31
CN107082782A (zh) 2017-08-22
WO2014143799A9 (en) 2014-12-24
US10399982B2 (en) 2019-09-03
CN107082782B (zh) 2020-03-20
WO2014143799A2 (en) 2014-09-18
EP2970303B3 (en) 2018-08-01
JP2016513717A (ja) 2016-05-16
CN105143229B (zh) 2017-06-30
DK2970303T3 (en) 2017-06-26
CN105143229A (zh) 2015-12-09
PH12015502141B1 (en) 2018-10-12
TWI609867B (zh) 2018-01-01
IL240216B (en) 2018-11-29
PT2970303T (pt) 2017-06-23
US20250034143A1 (en) 2025-01-30
US20140275071A1 (en) 2014-09-18
UY35488A (es) 2014-10-31
US20170305910A1 (en) 2017-10-26
RS56066B1 (sr) 2017-10-31
SI2970303T1 (sl) 2017-08-31
HRP20170840T1 (hr) 2017-09-08
BR112015021164A8 (pt) 2019-12-03
CA2899646A1 (en) 2014-09-18
MX2015011617A (es) 2016-04-25
US9969736B2 (en) 2018-05-15
JP6360149B2 (ja) 2018-07-18
MY189912A (en) 2022-03-21
KR102227629B1 (ko) 2021-03-16
ES2636835T7 (es) 2018-11-20
ZA201505414B (en) 2016-03-30
TW201533044A (zh) 2015-09-01
EP2970303B9 (en) 2017-09-20
EP2970303B1 (en) 2017-05-10
US11958854B2 (en) 2024-04-16
CY1119042T1 (el) 2018-01-10
CA2899646C (en) 2021-08-31
IL240216A0 (en) 2015-09-24
DK2970303T5 (en) 2018-01-02
HUE033528T4 (en) 2018-05-02
AU2014228206C1 (en) 2018-10-25
PL2970303T6 (pl) 2018-12-31
US20190322667A1 (en) 2019-10-24
UA117470C2 (uk) 2018-08-10
HUE033528T2 (hu) 2017-12-28
KR20150133233A (ko) 2015-11-27
PL2970303T3 (pl) 2017-08-31

Similar Documents

Publication Publication Date Title
PH12015502141A1 (en) Substituted xanthines and methods of use thereof
ZA202004557B (en) Modulatory polynucleotides
WO2014152287A3 (en) Substituted xanthines and methods of use thereof
MX2016004927A (es) Composiciones utiles para tratar trastornos relacionados con kit.
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
IN2015DN00127A (es)
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
MX2015012401A (es) Composiciones y metodos de alterar niveles de colesterol.
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
HK1217410A1 (zh) Erk抑制劑及其用途
ZA201505011B (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
IL241191B (en) Local compositions and kits that include them for the treatment of local disorders
EP3082819A4 (en) Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
MX2015012334A (es) Metodos y composiciones para el control de malezas.
UY37018A (es) Inhibidores bicíclicos de pad4
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
IL244182A0 (en) Preparations, methods and systems for the treatment of skin disorders
EP3046554A4 (en) TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
IN2013MU03641A (es)
GEP201706764B (en) Quinazolin-thf-amines as pde1 inhibitors
EP3089745A4 (en) Compounds, compositions, and methods for the treatment of cancers
MX2015016603A (es) Composiciones de corticosteroides.
EP2994156A4 (en) Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity

Legal Events

Date Code Title Description
FG Grant or registration